The primary benefit of palivizumab is the reduction in the risk of hospitalization due to severe RSV infection in high-risk infants. Clinical trials have shown that palivizumab can decrease hospitalizations related to RSV by up to 55%. This preventive measure is particularly important for neonates with underlying health conditions, as it can significantly reduce morbidity and the need for medical interventions such as mechanical ventilation.
